In older patients lymphoma is a frequent disease and diffuse large B-cell lymphoma (DLBCL) represents >60% of all lymphomas. Elderly patients with DLBCL are a heterogeneous population and the definition of elderly varies within the literature. Even though the combination of rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) is considered standard therapy for DLBCL, management of elderly patients remains challenging. Accurate selection of patients able to tolerate proper immune-chemotherapy is crucial and the comprehensive geriatric assessment based on age, comorbidities and functional abilities of daily living, may help to discriminate among fit, unfit or frail patients.